Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) Director Christy Jones sold 2,811 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $14.00, for a total value of $39,354.00. Following the completion of the transaction, the director directly owned 27,400 shares in the company, valued at $383,600. The trade was a 9.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christy Jones also recently made the following trade(s):
- On Thursday, May 21st, Christy Jones sold 1,998 shares of Beta Bionics stock. The shares were sold at an average price of $9.95, for a total value of $19,880.10.
Beta Bionics Price Performance
NASDAQ BBNX opened at $13.89 on Friday. The firm has a market cap of $618.94 million, a P/E ratio of -9.20 and a beta of 3.40. The stock’s 50-day moving average is $10.93 and its 200-day moving average is $17.19. Beta Bionics, Inc. has a one year low of $8.80 and a one year high of $32.71.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on BBNX shares. Robert W. Baird dropped their price target on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Bank of America dropped their price target on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research report on Monday, May 18th. UBS Group raised Beta Bionics to a “strong-buy” rating in a research report on Monday, February 9th. Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. Finally, Leerink Partners dropped their price target on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $19.70.
View Our Latest Research Report on Beta Bionics
Institutional Investors Weigh In On Beta Bionics
A number of hedge funds and other institutional investors have recently bought and sold shares of BBNX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Beta Bionics in the 1st quarter valued at approximately $95,000. Goldman Sachs Group Inc. acquired a new stake in Beta Bionics in the 1st quarter valued at approximately $715,000. Woodline Partners LP acquired a new stake in Beta Bionics in the 1st quarter valued at approximately $1,530,000. Strs Ohio acquired a new position in shares of Beta Bionics during the 1st quarter worth approximately $29,000. Finally, Rhumbline Advisers acquired a new position in shares of Beta Bionics during the 1st quarter worth approximately $158,000.
About Beta Bionics
Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.
At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.
Featured Articles
- Five stocks we like better than Beta Bionics
- From Industry Titans to Tiny Fish: 3 Key Stocks Insiders are Trading
- MarketBeat Week in Review – 06/01 – 06/05
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
